BRPI0717183A2 - Exendina ou análogo de exendina modificada por peg e composições e seu uso. - Google Patents
Exendina ou análogo de exendina modificada por peg e composições e seu uso.Info
- Publication number
- BRPI0717183A2 BRPI0717183A2 BRPI0717183-8A BRPI0717183A BRPI0717183A2 BR PI0717183 A2 BRPI0717183 A2 BR PI0717183A2 BR PI0717183 A BRPI0717183 A BR PI0717183A BR PI0717183 A2 BRPI0717183 A2 BR PI0717183A2
- Authority
- BR
- Brazil
- Prior art keywords
- exendin
- peg
- compositions
- modified
- analog
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610118326 | 2006-11-14 | ||
| CN200610118326.X | 2006-11-14 | ||
| CN2007101387187A CN101125207B (zh) | 2006-11-14 | 2007-07-23 | 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途 |
| CN200710138718.7 | 2007-07-23 | ||
| PCT/CN2007/003203 WO2008058461A1 (en) | 2006-11-14 | 2007-11-13 | Peg modified exendin or exendin analog and compositions and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0717183A2 true BRPI0717183A2 (pt) | 2015-06-16 |
| BRPI0717183B1 BRPI0717183B1 (pt) | 2019-05-21 |
| BRPI0717183B8 BRPI0717183B8 (pt) | 2021-05-25 |
Family
ID=39093398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0717183A BRPI0717183B8 (pt) | 2006-11-14 | 2007-11-13 | exendina ou análogo de exendina modificada por peg, composição e seu uso |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9175060B2 (pt) |
| EP (1) | EP2081957B1 (pt) |
| JP (2) | JP2010509248A (pt) |
| KR (1) | KR20090089316A (pt) |
| CN (2) | CN101125207B (pt) |
| AU (1) | AU2007321649B2 (pt) |
| BR (1) | BRPI0717183B8 (pt) |
| CA (2) | CA2933795C (pt) |
| RU (1) | RU2498814C2 (pt) |
| WO (1) | WO2008058461A1 (pt) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2416797A4 (en) | 2009-04-10 | 2013-04-24 | Amylin Pharmaceuticals Llc | AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE |
| CN101870728A (zh) | 2009-04-23 | 2010-10-27 | 派格生物医药(苏州)有限公司 | 新型Exendin变体及其缀合物 |
| CN101987868B (zh) * | 2009-07-30 | 2013-09-04 | 江苏豪森医药集团有限公司 | Glp-1类似物的衍生物或其可药用盐和用途 |
| AU2010321587A1 (en) | 2009-11-23 | 2012-06-07 | Amylin Pharmaceuticals, Inc. | Polypeptide Conjugate |
| CN102397558B (zh) | 2010-09-09 | 2013-08-14 | 中国人民解放军军事医学科学院毒物药物研究所 | Exendin-4类似物的定位聚乙二醇化修饰物及其用途 |
| CN106928341B (zh) * | 2011-03-30 | 2021-06-01 | 上海仁会生物制药股份有限公司 | 定点单取代聚乙二醇化Exendin类似物及其制备方法 |
| EP2755691B1 (en) * | 2011-09-07 | 2018-08-22 | Prolynx LLC | Hydrogels with biodegradable crosslinking |
| WO2013059323A1 (en) * | 2011-10-18 | 2013-04-25 | Prolynx Llc | Peg conjugates of exenatide |
| WO2013163162A1 (en) * | 2012-04-24 | 2013-10-31 | Amylin Pharmaceuticals, Llc | Site-specific enzymatic modification of exendins and analogs thereof |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| CN104961808B (zh) * | 2013-03-25 | 2018-09-04 | 中国牧工商(集团)总公司 | 用于制备牛口蹄疫o型肽疫苗的多肽及其制备方法和用途 |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| RU2573933C1 (ru) * | 2014-08-21 | 2016-01-27 | Дафот Энтерпрайсис Лимитед | Пептид для лечения сахарного диабета 2-го типа и его осложнений |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| CN106554403B (zh) | 2015-09-25 | 2021-08-31 | 博瑞生物医药（苏州）股份有限公司 | 艾塞那肽修饰物及其用途 |
| EP3426678B1 (en) * | 2016-03-10 | 2025-07-02 | Shenzhen Hightide Biopharmaceutical, Ltd. | Conjugates of islet neogenesis peptides and analogs, and methods thereof |
| EP3429608A4 (en) * | 2016-03-16 | 2019-12-11 | Prolynx LLC | CONJUGATES WITH EXTENDED RELEASE OF EXENATID ANALOG |
| CN107952064B (zh) * | 2016-10-14 | 2023-10-20 | 江苏豪森药业集团有限公司 | 含有聚乙二醇洛塞那肽的药物制剂及其制备方法 |
| CN109400695B (zh) | 2018-10-31 | 2020-06-30 | 中南大学湘雅医院 | 一种多肽的修饰方法及应用 |
| WO2020206358A1 (en) | 2019-04-05 | 2020-10-08 | Prolynx Llc | Improved conjugation linkers |
| WO2022002409A1 (en) * | 2020-07-02 | 2022-01-06 | Sanofi | Glp-1r agonistic peptides with reduced activity |
| CN114075275A (zh) * | 2020-08-17 | 2022-02-22 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
| CN114478694A (zh) * | 2020-11-13 | 2022-05-13 | 成都奥达生物科技有限公司 | 一种长效mc4r激动剂 |
| CN114478744A (zh) * | 2020-11-13 | 2022-05-13 | 成都奥达生物科技有限公司 | 一种长效glp-1拮抗剂 |
| WO2023055081A1 (ko) * | 2021-09-28 | 2023-04-06 | 한양대학교 산학협력단 | 암 치료용 글리시리진-분지형 폴리에틸렌글리콜 컨쥬게이트 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| DE60032331T2 (de) * | 1999-01-14 | 2007-06-21 | Amylin Pharmaceuticals, Inc., San Diego | Exendine zur glucagon suppression |
| EP1140145B2 (en) * | 1999-01-14 | 2019-05-15 | Amylin Pharmaceuticals, LLC | Novel exendin agonist formulations and methods of administration thereof |
| CN1372570A (zh) * | 1999-04-30 | 2002-10-02 | 安米林药品公司 | 修饰的exendin和exendin激动剂 |
| US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| CN1162446C (zh) * | 2001-05-10 | 2004-08-18 | 上海华谊生物技术有限公司 | 促胰岛素分泌肽衍生物 |
| ES2291620T3 (es) * | 2002-03-13 | 2008-03-01 | Beijing Jiankai Technology Co., Ltd. | Derivado de polimeros hidrfilicos con rama tipo y y metodo de preparacion de compuesto metodo que comprende el compuesto anterior. |
| CA2497794A1 (en) * | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
| EA009366B1 (ru) * | 2003-03-19 | 2007-12-28 | Эли Лилли Энд Компани | Связанные с полиэтиленгликолем соединения гпп-1 |
| CA2843439A1 (en) * | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd | Reversible pegylated drugs |
| AU2004298424A1 (en) * | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel GLP-1 compounds |
| CN100344323C (zh) * | 2004-09-30 | 2007-10-24 | 华东师范大学 | 一种人胰高血糖素样肽－1的复合物及其制备方法 |
| US7745516B2 (en) * | 2005-10-12 | 2010-06-29 | E. I. Du Pont De Nemours And Company | Composition of polyimide and sterically-hindered hydrophobic epoxy |
| WO2007047834A2 (en) | 2005-10-18 | 2007-04-26 | Biocon Limited | Oral peptide conjugates for metabolic diseases |
-
2007
- 2007-07-23 CN CN2007101387187A patent/CN101125207B/zh active Active
- 2007-07-23 CN CN201210248202.9A patent/CN102827284B/zh active Active
- 2007-11-13 EP EP07816815.0A patent/EP2081957B1/en active Active
- 2007-11-13 WO PCT/CN2007/003203 patent/WO2008058461A1/en not_active Ceased
- 2007-11-13 BR BRPI0717183A patent/BRPI0717183B8/pt active IP Right Grant
- 2007-11-13 US US12/514,790 patent/US9175060B2/en active Active
- 2007-11-13 CA CA2933795A patent/CA2933795C/en active Active
- 2007-11-13 CA CA002666182A patent/CA2666182A1/en not_active Abandoned
- 2007-11-13 AU AU2007321649A patent/AU2007321649B2/en active Active
- 2007-11-13 KR KR1020097009898A patent/KR20090089316A/ko not_active Ceased
- 2007-11-13 JP JP2009535548A patent/JP2010509248A/ja active Pending
- 2007-11-13 RU RU2009122582/10A patent/RU2498814C2/ru active
-
2013
- 2013-11-22 JP JP2013241844A patent/JP2014088384A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008058461A1 (en) | 2008-05-22 |
| JP2014088384A (ja) | 2014-05-15 |
| CN102827284B (zh) | 2015-07-29 |
| CN101125207B (zh) | 2012-09-05 |
| US20100240586A1 (en) | 2010-09-23 |
| CA2933795C (en) | 2019-01-08 |
| US9175060B2 (en) | 2015-11-03 |
| CA2666182A1 (en) | 2008-05-22 |
| EP2081957A4 (en) | 2013-05-08 |
| RU2498814C2 (ru) | 2013-11-20 |
| BRPI0717183B1 (pt) | 2019-05-21 |
| CA2933795A1 (en) | 2008-05-22 |
| BRPI0717183B8 (pt) | 2021-05-25 |
| AU2007321649B2 (en) | 2013-01-10 |
| EP2081957A1 (en) | 2009-07-29 |
| KR20090089316A (ko) | 2009-08-21 |
| CN101125207A (zh) | 2008-02-20 |
| AU2007321649A1 (en) | 2008-05-22 |
| JP2010509248A (ja) | 2010-03-25 |
| CN102827284A (zh) | 2012-12-19 |
| EP2081957B1 (en) | 2019-08-14 |
| RU2009122582A (ru) | 2010-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0717183A2 (pt) | Exendina ou análogo de exendina modificada por peg e composições e seu uso. | |
| BRPI0720124A2 (pt) | Composições farmacêuticas e seus métodos de uso. | |
| BRPI0720328A2 (pt) | Composição tensoativa e detergente ou limpador. | |
| BRPI0718182A2 (pt) | Oligorribonucleotídeos e seus usos. | |
| BRPI0614205A2 (pt) | composto, composição farmacêutica, e, uso de composto | |
| ATE482618T1 (de) | Wirkstoffkombinationen | |
| BRPI0719345A2 (pt) | Di-hidroimidazóis substituídos e seu uso no tratamento de tumores. | |
| BRPI0618904A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
| ATE484194T1 (de) | Wirkstoffkombinationen | |
| BRPI0910557A2 (pt) | composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso. | |
| BRPI0922435A2 (pt) | "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso." | |
| BRPI0907365A2 (pt) | Composição antimicrobiana e uso | |
| ITMI20050728A1 (it) | Formulazione innovativa | |
| BRPI0716171A2 (pt) | composto, composiÇço farmacÊutica e uso de um composto. | |
| BRPI0813627A2 (pt) | Peptídio antimicrobiano, composições e métodos de uso | |
| BRPI0719250A2 (pt) | Métodos e composições com opalescência reduzida. | |
| BRPI0911427A2 (pt) | complexo por dnl (dock and lock) de anticorpo-citocina, uso de uma composição farmaceutica. | |
| BRPI0718137A2 (pt) | Comutadores moleculares e métodos para seu uso | |
| BRPI0718192A2 (pt) | Corantes dispersos, sua preparação e seu uso. | |
| BRPI0816836A2 (pt) | Composições de limpeza e/ou tratamento | |
| CR10725A (es) | Compuestos de pirazolina y su uso y composiones farmaceuticas | |
| BRPI0915552A2 (pt) | derivados de ciclosporina, seu uso e sua composição farmacêutica | |
| BRPI0721216A2 (pt) | Composições de acetaminofen com efeitos colaterais minimizados e hepatotoxidez reduzida | |
| DE602006016137D1 (de) | Harzzusammensetzungen und harzformkörper | |
| BRPI0813453A2 (pt) | 3-ciclopropil-4-(3-tiobenzoil)pirazol e seu uso como herbicida. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION (CN) |
|
| B25G | Requested change of headquarter approved |
Owner name: SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION (CN) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: C07K 14/575 (2006.01), A61K 38/26 (2006.01), A61K |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/11/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |